195 related articles for article (PubMed ID: 19855172)
1. Evaluation of p63 and p73 antibodies for cross-reactivity.
Rosenbluth JM; Johnson K; Tang L; Triplett T; Pietenpol JA
Cell Cycle; 2009 Nov; 8(22):3702-6. PubMed ID: 19855172
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies raised against Xenopus p53 interact with human p73.
Le Bras M; Delattre V; Bensaad K; Blandino G; Soussi T
Oncogene; 2002 Feb; 21(8):1304-8. PubMed ID: 11850851
[TBL] [Abstract][Full Text] [Related]
3. Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry.
Nekulova M; Holcakova J; Nenutil R; Stratmann R; Bouchalova P; Müller P; Mouková L; Coates PJ; Vojtesek B
Virchows Arch; 2013 Sep; 463(3):415-25. PubMed ID: 23887585
[TBL] [Abstract][Full Text] [Related]
4. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.
Murray-Zmijewski F; Lane DP; Bourdon JC
Cell Death Differ; 2006 Jun; 13(6):962-72. PubMed ID: 16601753
[TBL] [Abstract][Full Text] [Related]
5. p63 and p73: roles in development and tumor formation.
Moll UM; Slade N
Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
[TBL] [Abstract][Full Text] [Related]
6. Detection of p73 antibodies in patients with various types of cancer: immunological characterization.
Tominaga O; Unsal K; Zalcman G; Soussi T
Br J Cancer; 2001 Jan; 84(1):57-63. PubMed ID: 11139314
[TBL] [Abstract][Full Text] [Related]
7. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
[TBL] [Abstract][Full Text] [Related]
8. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C
Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924
[TBL] [Abstract][Full Text] [Related]
9. p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance.
Hong SM; Cho H; Moskaluk CA; Yu E; Zaika AI
J Mol Histol; 2007 Jun; 38(3):167-75. PubMed ID: 17385050
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73.
Stiewe T; Stanelle J; Theseling CC; Pollmeier B; Beitzinger M; Pützer BM
J Biol Chem; 2003 Apr; 278(16):14230-6. PubMed ID: 12584188
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of two new members of the p53 family, p63 and p73, in extramammary Paget's disease.
Chen S; Moroi Y; Urabe K; Takeuchi S; Kido M; Hayashida S; Uchi H; Uenotsuchi T; Tu Y; Furue M
Clin Exp Dermatol; 2008 Aug; 33(5):634-40. PubMed ID: 18627398
[TBL] [Abstract][Full Text] [Related]
12. One, two, three--p53, p63, p73 and chemosensitivity.
Müller M; Schleithoff ES; Stremmel W; Melino G; Krammer PH; Schilling T
Drug Resist Updat; 2006 Dec; 9(6):288-306. PubMed ID: 17287142
[TBL] [Abstract][Full Text] [Related]
13. Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer.
Tannapfel A; Schmelzer S; Benicke M; Klimpfinger M; Kohlhaw K; Mössner J; Engeland K; Wittekind C
J Pathol; 2001 Sep; 195(2):163-70. PubMed ID: 11592094
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of the expression of p53, p63 and p73 in nasal and paranasal sinus carcinoma].
Zhang T; Jia H; Wang J; Shan Y; Luo S; Tang Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Oct; 22(20):919-21. PubMed ID: 19119599
[TBL] [Abstract][Full Text] [Related]
15. Expression of p63 and p73 in retinoblastoma: a clinicopathological correlation study.
Adithi M; Nalini V; Kandalam M; Krishnakumar S
Exp Eye Res; 2008 Oct; 87(4):312-8. PubMed ID: 18619959
[TBL] [Abstract][Full Text] [Related]
16. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53.
Davison TS; Vagner C; Kaghad M; Ayed A; Caput D; Arrowsmith CH
J Biol Chem; 1999 Jun; 274(26):18709-14. PubMed ID: 10373484
[TBL] [Abstract][Full Text] [Related]
17. P53 family: at the crossroads in cancer therapy.
Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
Vilgelm A; El-Rifai W; Zaika A
Drug Resist Updat; 2008; 11(4-5):152-63. PubMed ID: 18801697
[TBL] [Abstract][Full Text] [Related]
19. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Int J Cancer; 2002 May; 99(1):22-8. PubMed ID: 11948487
[TBL] [Abstract][Full Text] [Related]
20. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network.
Boominathan L
Cancer Metastasis Rev; 2010 Dec; 29(4):613-39. PubMed ID: 20922462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
